I believe Anavex anticipates growth, and it desires to be in a position to act quickly to raise capital as needed. Anavex has created many options to raise capital, which is good, but this is a quick, efficient and low cost way to do it. Why not file a shelf offering is a better question? And why not file only one, but make it large enough for the future - next 3 years. A shelf offering is good for 3 years. Personally, I believe, as Bio, that Anavex has high odds (80%) for a drug approval in the next few years. Before approval, the odds are high we will see positive clinical trial results. That will drive share price up and allow some shelf shares to be quickly issued to expand and accelerate further development.
80% odds and the high market potential for its drugs is a risk I am willing to take based on my DD done over the last four years. However, I advise everyone to do the extensive research and form their own opinions.
Market Data 
Markets 
